UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Management of antiphospholipid syndrome in pregnant and postpartum women

Authors
Charles J Lockwood, MD, MHCM
Michael D Lockshin, MD, MACR
Section Editors
Vincenzo Berghella, MD
David S Pisetsky, MD, PhD
Deputy Editors
Vanessa A Barss, MD, FACOG
Monica Ramirez Curtis, MD, MPH

INTRODUCTION

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by venous or arterial thrombosis and/or pregnancy loss in the presence of persistent antiphospholipid antibodies (aPL). It can occur as a primary condition, or it can occur with systemic lupus erythematosus (SLE) or another systemic autoimmune disease. Patients with SLE frequently have aPL, whereas the development of APS is much less common. aPL can also be found in healthy individuals. The main types of aPL of concern during pregnancy are lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta-2-glycoprotein-1 antibodies.

This topic will discuss the potential impact of APS and aPL alone during pregnancy, as well as the management of APS during pregnancy and postpartum. The medical management of women with non-obstetric APS and prenatal care of women with SLE with or without anti-Ro/SSA and anti-La/SSB antibodies are reviewed separately:

(See "Treatment of antiphospholipid syndrome".)

(See "Pregnancy in women with systemic lupus erythematosus".)

(See "Neonatal lupus: Management and outcomes", section on 'In utero management'.)

                           
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Sep 13, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295.
  2. Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3:e000131.
  3. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64:2311.
  4. Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 2017; 216:525.e1.
  5. Latino JO, Udry S, Aranda FM, et al. Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus 2017; 26:983.
  6. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211.
  7. Abrahams VM, Chamley LW, Salmon JE. Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation. Arthritis Rheumatol 2017; 69:1710.
  8. Tong M, Viall CA, Chamley LW. Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update 2015; 21:97.
  9. Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum 2012; 42:66.
  10. Breen KA, Seed P, Parmar K, et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012; 107:423.
  11. Salmon JE, Girardi G. The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun 2004; 7:133.
  12. Marder W, Knight JS, Kaplan MJ, et al. Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. Lupus Sci Med 2016; 3:e000134.
  13. Gysler SM, Mulla MJ, Guerra M, et al. Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8. Mol Hum Reprod 2016; 22:465.
  14. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14:131.
  15. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614.
  16. Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19:58.
  17. Tincani A, Rebaioli CB, Andreoli L, et al. Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 2009; 11:70.
  18. Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol 2006; 23:247.
  19. Pollard JK, Scott JR, Branch DW. Outcome of children born to women treated during pregnancy for the antiphospholipid syndrome. Obstet Gynecol 1992; 80:365.
  20. Botet F, Romera G, Montagut P, et al. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med 1997; 25:192.
  21. Ruffatti A, Dalla Barba B, Del Ross T, et al. Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol 1998; 16:605.
  22. Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med 1999; 27:183.
  23. Tincani A, Lojacono A, Taglietti M, et al. Pregnancy and neonatal outcome in primary antiphospholipid syndrome. Lupus 2002; 11:649.
  24. Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 2013; 72:217.
  25. Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus 2007; 16:634.
  26. Simchen MJ, Goldstein G, Lubetsky A, et al. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 2009; 40:65.
  27. Berkun Y, Simchen MJ, Strauss T, et al. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome? Lupus 2014; 23:986.
  28. Machado V, Pimentel S, Pinto F, Nona J. Perinatal ischemic stroke: a five-year retrospective study in a level-III maternity. Einstein (Sao Paulo) 2015; 13:65.
  29. Peixoto MV, de Carvalho JF, Rodrigues CE. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res 2014; 2014:672603.
  30. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991; 165:1272.
  31. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 1991; 325:1063.
  32. Soh MC, Pasupathy D, Gray G, Nelson-Piercy C. Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes. Rheumatology (Oxford) 2013; 52:1642.
  33. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.
  34. Bergrem A, Jacobsen EM, Skjeldestad FE, et al. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study. Thromb Res 2010; 125:e222.
  35. Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001; 184:825.
  36. Hornstein MD. Antiphospholipid antibodies in patients undergoing IVF: the data do not support testing. Fertil Steril 2000; 74:635.
  37. Hornstein MD, Davis OK, Massey JB, et al. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000; 73:330.
  38. Chighizola CB, de Jesus GR. Antiphospholipid antibodies and infertility. Lupus 2014; 23:1232.
  39. Levine AB, Lockshin MD. Assisted reproductive technology in SLE and APS. Lupus 2014; 23:1239.
  40. Yelnik CM, Porter TF, Branch DW, et al. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis Rheumatol 2016; 68:1964.
  41. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35:151.
  42. Polzin WJ, Kopelman JN, Robinson RD, et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 1991; 78:1108.
  43. Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161:369.
  44. Petri M. Diagnosis of antiphospholipid antibodies. Rheum Dis Clin North Am 1994; 20:443.
  45. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991; 34:1231.
  46. Petri M, Golbus M, Anderson R, et al. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum 1987; 30:601.
  47. Haddow JE, Rote NS, Dostal-Johnson D, et al. Lack of an association between late fetal death and antiphospholipid antibody measurements in the second trimester. Am J Obstet Gynecol 1991; 165:1308.
  48. Chaudhary RK, Nepal C, Khanal N, et al. Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review. Cardiovasc Hematol Agents Med Chem 2015; 13:92.
  49. Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216:110.
  50. Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol 2012; 120:1514. Reaffirmed 2017.
  51. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99:135.
  52. Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12:524.
  53. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50:1028.
  54. Kutteh WH, Rote NS, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am J Reprod Immunol 1999; 41:133.
  55. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010; 115:1256.
  56. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49:281.
  57. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318.
  58. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584.
  59. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313:1322.
  60. Farquharson RG, Pearson JF, John L. Lupus anticoagulant and pregnancy management. Lancet 1984; 2:228.
  61. Joffe AM, Hoskins CF, Ghitter-Mannes SC, Mant MJ. Anticoagulant therapy for prevention of spontaneous abortion in a patient with a lupus anticoagulant. Am J Hematol 1988; 29:56.
  62. Jungers P, Liote F, Dautzenberg MD, et al. Lupus anticoagulant and thrombosis in systemic lupus erythematosus. Lancet 1984; 1:574.
  63. van Hoorn ME, Hague WM, van Pampus MG, et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol 2016; 197:168.
  64. Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun Rev 2015; 14:446.
  65. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160:439.
  66. Del Ross T, Ruffatti A, Visentin MS, et al. Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol 2013; 40:425.
  67. Fishman P, Falach-Vaknin E, Sredni B, et al. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol 1995; 22:1086.
  68. Amengual O, Fujita D, Ota E, et al. Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. Lupus 2015; 24:1135.
  69. Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:71S.
  70. Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119:2624.
  71. Toubi E, Kessel A, Rosner I, et al. Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. Lupus 2003; 12:297.
  72. Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016; 214:273.e1.
  73. Bertolaccini ML, Contento G, Lennen R, et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun 2016; 75:30.
  74. Denis AL, Guido M, Adler RD, et al. Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients. Fertil Steril 1997; 67:1084.
  75. Chilcott IT, Margara R, Cohen H, et al. Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization. Fertil Steril 2000; 73:526.
  76. Steinvil A, Raz R, Berliner S, et al. Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost 2012; 108:1192.
  77. Orquevaux P, Masseau A, Le Guern V, et al. In Vitro Fertilization in 37 Women with Systemic Lupus Erythematosus or Antiphospholipid Syndrome: A Series of 97 Procedures. J Rheumatol 2017; 44:613.
  78. Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril 2008; 90:S172.
  79. American Society for Reproductive Medicine 56th annual meeting. October 21-26, 2000. San Diego, California, USA. Abstracts. Fertil Steril 2000; 74:S1.